Tag Archives: Year’s

CBO: Pelosi drug pricing bill would save government $345B over 10 years, but stifle new treatments

House Speaker Nancy Pelosi’s bill to let the government negotiate prices on some drugs would save the government $ 345 billion over seven years but stifle innovation of new treatments and cures, according to a new analysis from the Congressional Budget Office. Democrats are likely to use the findings, from an initial report from the… Read More »

Years after Cubist buyout, Merck scores a new Zerbaxa indication. Can it jump-start sales?

Merck hasn’t exactly made a fortune on its $ 9.5 billion Cubist Pharmaceuticals buyout, but now, a next-gen antibiotic it acquired in that deal has a brand-new indication that could help jump-start sales. On Monday, the FDA approved that drug, Zerbaxa, to treat adults with hospital-acquired and ventilator-associated pneumonia. It’s an add-on to Zerbaxa’s original approvals—to treat complicated… Read More »